Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06826729

The Characteristics of Blood Glucose Profile and the Changes of Hormones in PPDM-C Population

The purpose of this study was to explore the characteristics of blood glucose spectrum, changes of endocrine/exocrine pancreatic function and the correlation between them in patients with PPDM-C.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

The benefits of this study to participants include:

  • It will help to make early diagnosis or risk screening for the potential related risks and concomitant diseases of the disease;
  • Provide necessary suggestions for the treatment and intervention of the disease, or provide useful information for the related research of the disease.
  • We will provide Abbott version h dynamic glucose meter and assessment of internal and external secretion function. The researcher will provide professional endocrine related lifestyle and drug guidance for the subjects according to their CGMS data.

The risks that this study may bring to participants are:

There may be some very small risks in specimen collection, including transient pain, local cyanosis, etc. a few people will have mild dizziness or extremely rare needle infection.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female Chinese subjects;
  • Was ≥ 18 years old when signing the informed consent;
  • Patients with complete diagnosis of chronic pancreatitis; ④ Those who voluntarily signed informed consent; ⑤ Those who complete serum samples in multiple centers and put them into storage.

Exclusion criteria

  • Patients with impaired glucose tolerance but undiagnosed diabetes;
  • Patients with T1DM related autoimmune markers or other types of DM;
  • Patients with autoimmune pancreatitis, recurrent acute pancreatitis or acute onset of chronic pancreatitis;
  • Patients who underwent pancreatic surgery or related invasive procedures during treatment;
  • Previous or current malignant tumor; ⑥ Pregnancy or lactation; ⑦ Suffering from severe heart, liver or kidney dysfunction or malignant disease; ⑧ Failure to sign informed consent for cognitive impairment or other reasons.

Treatment and study plan

Primary outcomes

  1. Blood glucose profile characteristics of patients with PPDM-C

    Time frame: From February 2025 to December 2025

Sponsors and collaborators

Lead sponsor

Shanghai Changzheng Hospital

Other

Registry information

Official study title

The Characteristics of Blood Glucose Profile and the Changes of Endogenous and Exogenous Hormones in Patients with Post-chronic Pancreatitis Diabetes Mellitus

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Feb 14, 2025
Registry last updated
Feb 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.